Cancer Biopsy Market Report Scope & Overview:

The Cancer Biopsy Market was valued at USD 33.57 Billion in 2025 and is expected to reach USD 81.93 Billion by 2035, growing at a CAGR of 9.33% from 2026-2035.

Cancer biopsy encompasses the full range of procedures, instruments, and laboratory technologies used to sample and analyse suspicious tissue or, increasingly, tumour DNA circulating in a patient's bloodstream, to confirm a cancer diagnosis, determine its molecular characteristics, and guide treatment selection. The category spans everything from a conventional needle passed directly into a suspicious mass under image guidance through the comprehensive genomic profiling that modern precision oncology increasingly demands, and it has evolved from a purely diagnostic confirmation step into an ongoing tool for monitoring how a patient's cancer responds to treatment and evolves over time. Growth is supported by rising global cancer incidence that continues to expand the underlying population requiring diagnostic confirmation, growing demand for early diagnosis driven by well-established evidence that earlier detection meaningfully improves treatment outcomes, and continued technological advancement that has pushed the field well beyond conventional tissue sampling toward blood-based liquid biopsy testing capable of detecting and characterising cancer from a single blood draw. Genomic profiling has become an especially powerful growth engine of its own, as next-generation sequencing-based biopsy approaches increasingly drive treatment selection decisions that a purely histological tissue diagnosis alone could never support.

⮞In 2026, Guardant Health received FDA approval for Guardant360 Liquid CDx, described by the company as the largest FDA-approved liquid biopsy panel with a 100-fold wider genomic footprint than its predecessor, integrating genomic and epigenomic data from a single blood draw to guide treatment selection for advanced cancer patients, with the approval transferring seven existing companion diagnostic indications to the new assay and positioning it as the only FDA-approved liquid biopsy combining genomic and epigenomic profiling in one test.

U.S. Cancer Biopsy Market Overview

The U.S. Cancer Biopsy Market was valued at USD 10.99 Billion in 2025 and is expected to reach USD 25.19 Billion by 2035, growing at a CAGR of 8.65% from 2026-2035.

The U.S. Cancer Biopsy Market benefits from a substantial and rising cancer incidence rate, broad insurance and Medicare coverage increasingly extending to advanced liquid biopsy and genomic profiling technology, and the presence of leading diagnostics companies headquartered in the country that continue to compete intensely on genomic footprint breadth, clinical validation, and companion diagnostic breadth. Leading companies continue to expand their companion diagnostic indications at a genuinely rapid pace, with one leading liquid biopsy platform now carrying FDA approval for roughly two dozen distinct companion diagnostic applications spanning multiple cancer types and targeted therapies, reflecting just how central biopsy-derived molecular information has become to modern treatment selection. Continued inclusion of blood-based screening tests within major cancer screening guideline recommendations, combined with expanding commercial insurer coverage decisions, continues to widen the population of patients for whom liquid biopsy represents a genuinely accessible, reimbursed diagnostic option rather than an out-of-pocket expense. Continued clinical evidence generation and regulatory approval activity are expected to sustain strong demand growth throughout the forecast period.

⮞In 2026, Guardant Health reported that its Shield blood test achieved inclusion in the American Cancer Society's updated colorectal cancer screening guidelines and obtained coverage from UnitedHealth Group, the first major commercial insurer to provide coverage for the test, while the company also received FDA approval for a higher-throughput, lower-cost-of-goods Shield workflow designed to support continued scaling of blood-based colorectal cancer screening across its commercial launch nationwide.

By Product Type, Kits and Consumables Dominates the Market and Instruments Grows Fastest

Kits and consumables dominated the market in 2025 with a 46.85% share, reflecting the fundamentally recurring nature of biopsy procedure volume, where every tissue sample collected or blood draw processed consumes a fresh set of collection kits, reagents, and laboratory consumables regardless of how many times the underlying capital equipment has already been used. This recurring consumption pattern continues to generate a steady, predictable revenue stream that scales directly with rising global biopsy procedure volume, and this fundamental demand dynamic continues to anchor kits and consumables as the largest product type category across the broader cancer biopsy market by a considerable margin over standalone instrument sales.

Instruments are projected to be the fastest-growing product type over the forecast period, registering a CAGR of 10.75%, as advancements in biopsy technology continue to drive replacement demand for increasingly precise, image-guided, and automated sampling devices capable of delivering more diagnostically useful tissue with less patient discomfort and procedural risk than earlier-generation instruments provided. Continued demand for increasingly precise diagnostic tools, particularly for image-guided procedures targeting small, difficult-to-access lesions, continues to drive above-market growth for instruments relative to the broader kits-and-consumables-dominated product type mix.

⮞In March 2026, Mammotome received U.S. FDA clearance for its Prima MR dual vacuum-assisted breast biopsy system, designed for placement inside the MRI scanner room, alongside its HydroMARK Plus MR biopsy site markers. The launch advances MRI-guided breast tissue sampling and procedural workflow integration.

By Procedure Type, Tissue Biopsies Dominates the Market and Liquid Biopsy Grows Fastest

Tissue biopsies dominated the market in 2025 with a 61.40% share. Physically removing a sample of suspicious tissue for pathological examination remains the established diagnostic gold standard across the overwhelming majority of cancer diagnoses, providing pathologists with the direct histological and architectural information that remains genuinely difficult to replace entirely, and this fundamental clinical role continues to anchor tissue biopsies as the clear largest procedure type category across the broader cancer biopsy market.

Liquid biopsy is projected to be the fastest-growing procedure type over the forecast period, registering a CAGR of 14.85%, as blood-based testing for circulating tumour DNA and related biomarkers continues to offer genuine advantages in situations where a physical tissue sample is difficult, risky, or impossible to obtain, and increasingly as a practical, repeatable tool for monitoring treatment response over time without requiring repeated invasive procedures. Continued regulatory approval of increasingly comprehensive liquid biopsy panels, combining genomic and epigenomic profiling within a single blood draw, continues to drive sustained above-market growth for this procedure type relative to the broader tissue-biopsy-dominated procedure mix.

⮞In April 2025, Natera announced the broad clinical launch of its Signatera Genome assay in the United States. The whole-genome-based, circulating tumor DNA test expands molecular residual disease testing capabilities and supports cancer recurrence monitoring across multiple solid tumor types.

By Cancer Type, Breast Cancer Dominates the Market and Pancreatic Cancer Grows Fastest

Breast cancer dominated the market in 2025 with a 26.75% share. The sheer global incidence of breast cancer, combined with well-established screening and diagnostic protocols that routinely incorporate biopsy confirmation following an abnormal mammogram or clinical finding, continues to anchor breast cancer as the largest cancer type category across the broader cancer biopsy market, reflecting decades of accumulated clinical infrastructure specifically built around breast cancer detection and diagnosis.

Pancreatic cancer is projected to be the fastest-growing cancer type over the forecast period, registering a CAGR of 11.65%, as liquid biopsy technology finally offers a genuinely practical surveillance method for high-risk patient cohorts, a population that historically lacked any reliable early detection option given how difficult pancreatic tissue has traditionally been to safely access for conventional tissue sampling. Continued advancement in blood-based screening technology specifically suited to this historically underserved cancer type continues to drive above-market growth for pancreatic cancer relative to the broader breast-cancer-dominated cancer type mix.

⮞In 2025, the U.S. National Cancer Institute listed the ExoLuminate study evaluating the ExoVerita blood-based assay for earlier detection of pancreatic ductal adenocarcinoma in elevated-risk and clinically suspicious patients. The registry-based study compares assay performance with established surveillance approaches.

By End User, Hospitals Dominates the Market and Ambulatory Surgical Centers Grows Fastest

Hospitals dominated the market in 2025 with a 42.60% share. The clinical infrastructure, specialist staffing, and imaging capability that complex biopsy procedures require continue to concentrate the largest share of overall procedure volume within hospital settings, particularly for image-guided and surgical biopsy procedures that demand the broader diagnostic and procedural support only hospitals reliably provide, sustaining hospitals' position as the largest end-user category across the broader market.

Ambulatory surgical centers are projected to be the fastest-growing end-user category over the forecast period, registering a CAGR of 12.85%, as a growing share of lower-complexity biopsy procedures continues to shift toward these more cost-effective, outpatient-focused settings capable of delivering comparable clinical quality at meaningfully lower overall procedure cost than a full hospital setting requires. Continued growth in outpatient procedural capacity continues to drive above-market growth for this end-user category relative to the broader hospital-dominated end-user mix.

⮞In February 2026, Germany's German Cancer Research Center reported research demonstrating that cell-free DNA from cerebrospinal fluid could support more precise classification of common brain tumors in children and adolescents. The work highlights opportunities for hospital-based neuro-oncology services to incorporate less invasive molecular diagnostic approaches.

By Application, Cancer Diagnosis and Staging Dominates the Market and Treatment Monitoring Grows Fastest

Cancer diagnosis and staging dominated the market in 2025 with a 49.75% share. Confirming an initial cancer diagnosis and determining how far the disease has progressed continues to represent the most fundamental and universal application driving biopsy procedure volume, as essentially every newly suspected cancer case requires some form of biopsy confirmation before treatment can meaningfully begin, sustaining this application's position as the clear leading category across the broader cancer biopsy market.

Treatment monitoring is projected to be the fastest-growing application over the forecast period, registering a CAGR of 13.15%, as rising adoption of liquid biopsy technology continues to make repeated, longitudinal monitoring of treatment response genuinely practical in a way that repeated invasive tissue sampling never could support at scale. Continued growth in precision oncology treatment approaches, which increasingly depend on ongoing molecular monitoring to detect treatment resistance early, continues to drive above-market growth for this application relative to the broader diagnosis-and-staging-dominated application mix.

⮞In September 2026, the U.S. FDA approved Guardant360 CDx as a companion diagnostic to identify ESR1 mutations in advanced breast cancer patients who may benefit from AstraZeneca's ETCAMAH (camizestrant). The approval supports serial blood-based molecular testing to identify emerging resistance-associated mutations before radiographic progression.

Regional Analysis

North America Cancer Biopsy Market Insights

North America dominated the market with a 39.85% share in 2025, anchored overwhelmingly by the United States, which alone represents a substantial majority of overall regional revenue. Growing demand for personalised medicine, broad awareness regarding cancer and biopsy techniques among both physicians and patients, and the concentration of leading diagnostics companies headquartered within the region, actively pursuing genomic and liquid biopsy innovation, continue to sustain this leadership position across every major procedure type and application category. The region's deep clinical trial and regulatory infrastructure further reinforces this leadership, as the majority of pivotal liquid biopsy and companion diagnostic approvals continue to originate from U.S.-based regulatory review, giving patients within the country earlier access to newly approved technology than many international markets typically experience.

Canada contributes meaningful incremental regional demand through its own publicly funded healthcare system and comparable clinical oncology infrastructure. Continued genomic profiling innovation and expanding commercial insurer coverage among leading diagnostics companies is expected to keep North America in the lead through the forecast period, even as its growth rate trails the faster-scaling markets developing across Asia Pacific.

⮞In March 2026, the U.S. FDA approved Perimeter Medical Imaging AI's Claire OCT System as an adjunctive imaging tool for examining excised breast tissue during lumpectomy procedures in patients with biopsy-confirmed breast cancer. The system combines real-time three-dimensional optical coherence tomography imaging with AI-assisted identification of suspicious tissue areas.

Asia Pacific Cancer Biopsy Market Insights

Asia Pacific is projected to be the fastest-growing region over the forecast period, registering a CAGR of approximately 12.45%. Rapidly rising cancer incidence, expanding hospital and diagnostic laboratory infrastructure, and growing government investment in national cancer screening programs across the region's major economies continue to accelerate regional adoption of advanced cancer biopsy technology.

China anchors regional demand through its enormous patient population and rapidly expanding domestic molecular diagnostics manufacturing capability. Japan and South Korea contribute additional regional depth through established oncology research infrastructure and early access to advanced genomic profiling technology, while India's rapidly expanding private healthcare sector continues to add meaningful incremental regional growth as rising cancer awareness and diagnostic capability continue to improve.

⮞In January 2026, China's National Medical Products Administration granted marketing approval to Prophet Genomics' chromosome-abnormality detection kit for urothelial carcinoma through its Green Channel review pathway. The urine-based sequencing test provides a non-invasive diagnostic aid for suspected urothelial cancer, expanding China's domestic molecular oncology diagnostics portfolio.

Europe Cancer Biopsy Market Insights

Europe holds a significant share of the global market, anchored by Germany's substantial healthcare infrastructure and the region's well-developed clinical research tradition, which continues to contribute meaningfully to the global evidence base supporting both established tissue biopsy and emerging liquid biopsy technology.

The United Kingdom, France, and Italy add consistent regional demand as national health systems continue extending access to advanced genomic profiling and liquid biopsy technology for patients with advanced cancer. Continued regional investment in national cancer screening programs is expected to sustain steady growth across the broader European market through the forecast period.

⮞In October 2026, Guardant Health announced European CE marking for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH (camizestrant) in advanced ER-positive, HER2-negative breast cancer. The authorization enables blood-based ESR1 mutation testing to help guide treatment decisions before radiographic disease progression.

MEA and Latin America Cancer Biopsy Market Insights

The Middle East and Africa region is supported by growing healthcare infrastructure investment across the United Arab Emirates and Saudi Arabia, where regional governments continue expanding oncology diagnostic capacity as part of broader healthcare modernisation strategies targeting rising cancer incidence across increasingly urbanised regional populations.

Latin America is anchored by Brazil, where a growing domestic healthcare sector sustains steady demand for cancer biopsy technology across both established tissue and increasingly liquid biopsy approaches. Mexico contributes further incremental growth as regional cancer screening access and diagnostic capability continue to expand gradually across the broader region.

⮞In January 2026, Saudi Arabia's Health Holding Company introduced its Taakkad preventive screening initiative, including an advanced screening package for early detection of selected cancers such as breast and colorectal cancer. The initiative also outlined plans for a future package incorporating genomics and proteomics, supporting expansion of preventive diagnostics.

Market Dynamics

Growth Drivers: Rising Cancer Incidence and Liquid Biopsy Technology Advancement

Rising global cancer incidence stands as the primary growth driver, as growing cancer diagnosis volumes worldwide, driven by ageing populations and evolving lifestyle and environmental risk factors, continue to directly expand the underlying patient population requiring biopsy confirmation, molecular characterisation, and ongoing treatment monitoring across virtually every major cancer type.

Growing demand for early diagnosis represents a second major driver, as well-established clinical evidence linking earlier cancer detection to meaningfully improved treatment outcomes continues to drive expanding screening program adoption and earlier biopsy-based diagnostic confirmation. Continued technological advancement in liquid biopsy and genomic profiling technology further reinforces sustained market demand, as these approaches continue to make earlier, less invasive detection and ongoing monitoring genuinely practical in ways conventional tissue sampling alone never could support at population scale.

⮞In June 2025, Natera announced that Medicare coverage for its Signatera Genome assay had been established under Local Coverage Determination L38779. The coverage includes specified cancer indications and pan-cancer immunotherapy monitoring, supporting patient access to genome-based circulating tumor DNA testing for molecular residual disease assessment.

Restraints: High Advanced Diagnostic Cost and Reimbursement Variability

High cost for advanced genomic and liquid biopsy diagnostic technology remains a genuine restraint, as the price of comprehensive genomic and epigenomic profiling panels continues to exceed conventional tissue biopsy substantially, creating meaningful access barriers for patients in markets with more limited specialty diagnostic reimbursement coverage.

Reimbursement variability presents a further restraint, as insurance and government healthcare coverage for newer liquid biopsy and genomic profiling technology continues to vary considerably between countries, and in some cases between individual insurers within the same country, creating genuine uncertainty for both patients and prescribing physicians when deciding which diagnostic pathway to pursue for a given clinical presentation.

Opportunities: Genomic Profiling Innovation and Expanding Screening Guideline Inclusion

Continued advancement of comprehensive genomic and epigenomic profiling technology represents a substantial opportunity, as companies that can deliver genuinely broader, more clinically actionable molecular information from a single test stand to capture demand from oncologists increasingly seeking comprehensive treatment selection guidance from a single diagnostic procedure.

Continued inclusion of blood-based tests within national cancer screening guideline recommendations offers a further avenue for growth, as companies that can secure formal guideline inclusion and expanding commercial insurer coverage are positioned to capture substantial new demand from a screening-eligible population that continues to expand well beyond the symptomatic, already-diagnosed patients that biopsy technology has traditionally served.

⮞In March 2026, India's Ministry of Health and Family Welfare announced the Cancer AI & Technology Challenge grant program under the IndiaAI Mission, in partnership with the National Cancer Grid. The initiative offers milestone-based funding for developing, piloting, and validating AI solutions across cancer screening, diagnostics, and care.

Cancer Biopsy Market Key Players are

• Becton, Dickinson and Company

• Hologic, Inc.

• Danaher Corporation

• Thermo Fisher Scientific Inc.

• Roche Holding AG

• Guardant Health, Inc.

• Exact Sciences Corporation

• Illumina, Inc.

• Merit Medical Systems, Inc.

• Argon Medical Devices, Inc.

• Boston Scientific Corporation

• Cook Medical LLC

• CONMED Corporation

• Devicor Medical Products, Inc. (Mammotome)

• Medtronic plc

• Cardinal Health, Inc.

• Olympus Corporation

• Fujifilm Holdings Corporation

• Bio-Rad Laboratories, Inc.

• Natera, Inc.

Cancer Biopsy Market Report Scope: